Latest Administration News

Conrad Asia Energy reports solid progress in Q4 2024 with finalized gas sales agreements and promising LNG studies, despite delayed final investment decisions due to regulatory approvals.

FAR Limited reports robust production from Senegal’s Sangomar field and a solid cash position, while anticipating a contingent payment from Woodside Energy that could reach US$55 million.

Raptis Group Limited reported a positive net cash inflow from operating activities of $54,509 for the quarter ended December 31, 2024, ending with $303,102 in cash and equivalents. The company recorded no investing or financing cash flows during the period.

CAQ Holdings Limited reported an 8% decrease in leasing revenue for the December 2024 quarter, as tenant negotiations continue amid uncertain government policies affecting the Hainan free trade port development.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Regional Express Holdings has completed the transfer of debt from PAGAC Regulus Holding to the Commonwealth of Australia, marking a key step in its ongoing administration process.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

Regional Express Holdings has assigned a $50 million portion of its debt to the Commonwealth of Australia, making the government the largest secured creditor as the airline navigates voluntary administration.

Vonex Limited reported a net cash inflow of $779,000 from operating activities in Q4 2024, maintaining a solid cash position despite accelerated debt repayments following a change of control.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

The Calmer Co. International Limited has reported a remarkable surge in sales and cash receipts for the first half of FY25, exceeding the entire FY24 sales. Alongside a strategic CEO transition and factory upgrade, the company is sharpening its focus on profitable growth and cost control.

Forbidden Foods Limited has more than doubled its group revenues in Q2 FY25 following the acquisition of Oat Milk Goodness, driven by expanded retail distribution and strong ecommerce growth.